Wenjie Qi

Wenjie Qi

Auto-generated profile, based on publicly available information

Wenjie Qi

Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, Tennessee, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MHMinghong He
Minghong He
XZXinying Zong
Xinying Zong
BXBeisi Xu
Beisi Xu
WQWenjie Qi
Wenjie Qi
WHWenjun Huang
Wenjun Huang
YFYongqiang Feng
Yongqiang Feng
Nuclear factor Foxp3 determines regulatory T (Treg) cell fate and function via mechanisms that remain unclear. Here, we investigate the nature of Foxp3-mediated gene regulation in suppressing autoimmunity and antitumor immune response. Contrasting with previous models, we find that Foxp3–chromatin binding is regulated by Treg activation states, tumor microenvironment, and antigen and cytokine stimulations. Proteomics studies uncover dynamic proteins within Foxp3 proximity upon TCR or IL-2 receptor signaling in vitro, reflecting intricate interactions among Foxp3, signal transducers, and chromatin. Pharmacological inhibition and genetic knockdown experiments indicate that NFAT and AP-1 protein Batf are required for enhanced Foxp3–chromatin binding in activated Treg cells and tumor-infiltrating Treg cells to modulate target gene expression. Furthermore, mutations at the Foxp3 DNA-binding domain destabilize the Foxp3–chromatin association. These representative settings delineate context-dependent Foxp3–chromatin interaction, suggesting that Foxp3 associates with chromatin by hijacking DNA-binding proteins resulting from Treg activation or differentiation, which is stabilized by direct Foxp3–DNA binding, to dynamically regulate Treg cell function according to immunological contexts.

3 November 2025 in Blood Cancer Discovery
Verified
Journal Article
Open access
JBJuan M. Barajas
Juan M. Barajas
APAaron H. Phillips
Aaron H. Phillips
JWJina Wang
Jina Wang
MTMelvin Thomas
Melvin Thomas
LCLisett Contreras
Lisett Contreras
JKJeffery M. Klco
Jeffery M. Klco
UBTF tandem duplications (UBTF-TD) define a high-risk molecular subtype of acute myeloid leukemia (AML). Although menin inhibitors show therapeutic promise in UBTF-TD AMLs, acquired resistance remains a challenge. In this study, we used proteomic, epigenetic, and functional analyses to uncover mechanisms underlying UBTF-TD leukemogenesis. Biochemical studies showed that UBTF-TDs result in structural destabilization and create nuclear export signal (NES) motifs, which mediate direct interactions with exportin-1 (XPO1). In cord blood CD34+ UBTF-TD models, these interactions were shown to drive aberrant chromatin binding and transcriptional activation of genes dysregulated in UBTF-TD tumors. Through mutagenesis, we demonstrated that these NES motifs are critical for localization of UBTF-TD proteins to chromatin, transcriptional dysregulation, and cellular proliferation and differentiation. In preclinical UBTF-TD models of human leukemia, we found that XPO1 inhibition disrupts UBTF-TD chromatin localization, reduces tumor burden, and promotes differentiation. These mechanistic findings highlight XPO1 inhibition as a potential therapy for UBTF-TD AMLs. Significance: UBTF tandem duplications are a high-risk AML subtype. We identified a mechanism in which UBTF-TDs result in the generation of NES motifs, enabling aberrant interaction with XPO1. We found that XPO1 inhibitors block this interaction and impair leukemia growth, identifying a possible therapeutic strategy in UBTF-TD AML. See related commentary by Adams, p. 15

12 January 2026
Verified
Other
Open access
JBJuan M. Barajas
Juan M. Barajas
APAaron H. Phillips
Aaron H. Phillips
JWJina Wang
Jina Wang
MTMelvin Thomas
Melvin Thomas
LCLisett Contreras
Lisett Contreras
JKJeffery M. Klco
Jeffery M. Klco
Flow cytometry analysis in UBTF-TD PDX models. (A) Gating strategy for peripheral blood and bone marrow used in Figures 6 and 7. (B–C) Representative plots and summary of peripheral blood chimerism following eltanexor treatment. (D–E) Representative flow cytometry plots from Figures 6D and 7E.

12 January 2026
Verified
Other
Open access
JBJuan M. Barajas
Juan M. Barajas
APAaron H. Phillips
Aaron H. Phillips
JWJina Wang
Jina Wang
MTMelvin Thomas
Melvin Thomas
LCLisett Contreras
Lisett Contreras
JKJeffery M. Klco
Jeffery M. Klco
Eltanexor treatment in primary human cells. (A–B) Flow cytometry gating and representative plots related to Figures 5C–E. (C) CellTiter-Glo assay in CD34⁺ cells expressing UBTF-TD or UBTF-TD-NES-M. (D) HOXA/B gene expression heatmap after DMSO, dTAG-13, or eltanexor treatment. (E) UpSet plot showing UBTF-TD and XPO1 gene occupancy changes. (F–G) Design and results of colony-forming assays in UBTF-TD PDX cells treated with eltanexor.

12 January 2026
Verified
Other
Open access
JBJuan M. Barajas
Juan M. Barajas
APAaron H. Phillips
Aaron H. Phillips
JWJina Wang
Jina Wang
MTMelvin Thomas
Melvin Thomas
LCLisett Contreras
Lisett Contreras
JKJeffery M. Klco
Jeffery M. Klco
Panel A shows western blot analysis (anti-HA) of cbCD34⁺ cell lysates transduced with various HA-tagged UBTF constructs and vector control. Panel B presents RNA-seq tracks visualized in IGV, highlighting soft-clipped reads that indicate tandem duplications and the expressed cDNA sequences. Panel D-F depict gating strategies and representative flow plots

12 January 2026
Verified
Other
Open access
JBJuan M. Barajas
Juan M. Barajas
APAaron H. Phillips
Aaron H. Phillips
JWJina Wang
Jina Wang
MTMelvin Thomas
Melvin Thomas
LCLisett Contreras
Lisett Contreras
JKJeffery M. Klco
Jeffery M. Klco
Illustrates chromatin protein interactions involving UBTF-TD54–NES-M in K562 cells using qPLEX-RIME. Panel A outlines the experimental design. Panels B and C present volcano plots comparing UBTF-TD54–NES-M to UBTF-WT and NES-M, respectively.